Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium

PLoS One. 2011;6(11):e27910. doi: 10.1371/journal.pone.0027910. Epub 2011 Nov 28.

Abstract

Although chronic hypoxia is a claimed myocardial risk factor reducing tolerance to ischemia/reperfusion (I/R), intermittent reoxygenation has beneficial effects and enhances heart tolerance to I/R.

Aim of the study: To test the hypothesis that, by mimicking intermittent reoxygenation, selective inhibition of phosphodiesterase-5 activity improves ischemia tolerance during hypoxia. Adult male Sprague-Dawley rats were exposed to hypoxia for 15 days (10% O₂) and treated with placebo, sildenafil (1.4 mg/kg/day, i. p.), intermittent reoxygenation (1 h/day exposure to room air) or both. Controls were normoxic hearts. To assess tolerance to I/R all hearts were subjected to 30-min regional ischemia by left anterior descending coronary artery ligation followed by 3 h-reperfusion. Whereas hypoxia depressed tolerance to I/R, both sildenafil and intermittent reoxygenation reduced the infarct size without exhibiting cumulative effects. The changes in myocardial cGMP, apoptosis (DNA fragmentation), caspase-3 activity (alternative marker for cardiomyocyte apoptosis), eNOS phosphorylation and Akt activity paralleled the changes in cardioprotection. However, the level of plasma nitrates and nitrites was higher in the sildenafil+intermittent reoxygenation than sildenafil and intermittent reoxygenation groups, whereas total eNOS and Akt proteins were unchanged throughout.

Conclusions: Sildenafil administration has the potential to mimic the cardioprotective effects led by intermittent reoxygenation, thereby opening the possibility to treat patients unable to be reoxygenated through a pharmacological modulation of NO-dependent mechanisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Body Weight / drug effects
  • Cardiomegaly / blood
  • Cardiomegaly / complications
  • Cardiomegaly / enzymology
  • Cardiomegaly / pathology
  • Cardiotonic Agents / pharmacology*
  • Cell Hypoxia / drug effects
  • Cyclic Nucleotide Phosphodiesterases, Type 5 / metabolism*
  • Male
  • Myocardial Infarction / blood
  • Myocardial Infarction / complications
  • Myocardial Infarction / pathology
  • Myocardium / enzymology*
  • Myocardium / pathology*
  • Nitric Oxide / blood
  • Nitric Oxide Synthase Type III / metabolism
  • Oxygen / metabolism*
  • Phosphodiesterase 5 Inhibitors / pharmacology*
  • Polycythemia / blood
  • Polycythemia / complications
  • Polycythemia / pathology
  • Proto-Oncogene Proteins c-akt / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction / drug effects

Substances

  • Cardiotonic Agents
  • Phosphodiesterase 5 Inhibitors
  • Nitric Oxide
  • Nitric Oxide Synthase Type III
  • Proto-Oncogene Proteins c-akt
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Oxygen